Last reviewed 2026-04-20 · How we verify

Delstrigo

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in people with concomitant HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DELSTRIGO. If appropriate, initiation of ant

Common side effects

• Neuropsychiatric adverse events
• Dizziness
• Nausea
• Abnormal dreams
• Sleep disorders and disturbances
• Depression
• Altered sensorium

Serious adverse events

• Suicide/self-injury
• Adverse events leading to discontinuation

Key clinical trials

• Doravirine Dose Optimisation in Pregnancy (PHASE4)
• Efficacy and Safety of Doravirine in the Rapid Initiation (PHASE4)
• DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (PHASE3)
• Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study (PHASE4)
• DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) (PHASE2)
• Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? (PHASE4)
• A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy (PHASE3)
• Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.